{"id":189,"date":"2026-06-08T02:59:54","date_gmt":"2026-06-08T02:59:54","guid":{"rendered":"https:\/\/eieling.com\/?page_id=189"},"modified":"2026-09-16T10:13:23","modified_gmt":"2026-09-16T10:13:23","slug":"liver-health","status":"publish","type":"page","link":"https:\/\/eieling.com\/tc\/liver-health\/","title":{"rendered":"\u809d\u81df\u5065\u5eb7"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Fatty Liver, Fibrosis & Liver Health Resources<\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t
home > Liver Health<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

LIVER HEALTH<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Your Liver, Your Metabolic Dashboard<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tAn education-first resource to help patients, healthcare partners, and distributors understand liver health \u2014 before discussing any product, evidence, or clinical pathway.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

1 in 4<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Adults affected by MASLD globally<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

~70%<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Of type 2 diabetes patients have fatty liver<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

50-80%<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Are undiagnosed in early stages<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

WHY NOW<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Why Liver Health Matters Now<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide \u2014 affecting over 1 billion people. Yet most have never had their liver fat measured. The convergence of obesity, diabetes, and the GLP-1 revolution has made liver assessment a mainstream metabolic health priority.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The Silent Epidemic<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MASLD often progresses without symptoms for years. By the time elevated liver enzymes appear, significant fat accumulation may already be present. Early detection through quantitative assessment changes this \u2014 turning an invisible risk into a measurable, manageable health metric.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t

The GLP-1 Era Changes Everything<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

With GLP-1 receptor agonists now approved for weight management and MASH treatment, liver fat monitoring has shifted from specialist niche to mainstream metabolic care. Every weight management program now has a reason to track liver fat \u2014 creating a new standard of care and a rapidly growing market.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

1<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Identify Risk<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tRecognize metabolic risk factors – obesity, diabetes, dyslipidemia, family history.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

2<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Measure<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tQuantitative liver fat and stiffness assessment with accessible point-of-care tools.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

3<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Track & Compare<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tEstablish baseline values; track changes over time with objective, numeric data.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

4<\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Act with Confidence<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tShare objective data with clinicians; make informed follow-up and treatment decisions.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

EDUCATION TOPICS<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Start With the Questions People Actually Ask<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tAn education hub for anyone – patient, clinician, or business partner. Tap any topic below to explore the essentials, with source citations throughout.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/circle><\/path><\/g><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Understanding NAFLD \/ MASLD<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

What fatty liver disease means, why the terminology changed, and why early stages are silent.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

Read more >><\/h4>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
    \n
  • NAFLD \u2192 MASLD:<\/strong> In 2023, global liver societies renamed the condition to emphasize its metabolic roots. \u201cMASLD\u201d replaces \u201cNAFLD\u201d \u2014 the same disease, but a name that reflects its connection to metabolic health.<\/li>\n
  • Spectrum of disease:<\/strong> Simple steatosis (fat accumulation) \u2192 MASH (inflammation + fat) \u2192 fibrosis \u2192 cirrhosis. Each stage is measurable and, in early stages, reversible.<\/li>\n
  • The danger of silence:<\/strong> Most people with early-stage fatty liver have no symptoms. Liver enzymes can remain normal even with significant fat accumulation \u2014 blood tests alone are insufficient for screening.<\/li>\n<\/ul>\n
    Sources: AASLD Practice Guidance (Hepatology, 2023); Rinella ME et al., multi-society Delphi consensus on NAFLD nomenclature.<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t<\/circle><\/path><\/path><\/g><\/g><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t\t

    GLP-1 & Liver Health<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Why liver fat monitoring is becoming part of metabolic care in the GLP-1 era.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t\t

    Read more >><\/h4>\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t
      \n
    • Beyond weight loss:<\/strong> GLP-1 receptor agonists (semaglutide, tirzepatide) don\u2019t just reduce body weight \u2014 they directly impact liver fat. FDA approved Wegovy for MASH treatment in August 2025, making liver monitoring a standard component of metabolic care.<\/li>\n
    • Baseline matters:<\/strong> A quantitative liver fat measurement at the start of a weight management program establishes a clear starting point \u2014 enabling objective tracking alongside weight, glucose, and metabolic markers.<\/li>\n
    • Monitoring over time:<\/strong> Follow-up liver fat assessments help clinicians discuss metabolic progress with patients, reinforcing adherence and providing tangible feedback beyond the scale.<\/li>\n<\/ul>\n
      FDA CDER (2025-08-27): VCTE-measured liver stiffness accepted as surrogate endpoint for MASH trials. Educational content \u2014 not treatment advice.<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t
      \n\t\t\t
      \n\t\t\t<\/circle><\/path><\/g><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t\t

      Metabolic Health & Liver<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      The connection between obesity, insulin resistance, diabetes, and liver fat accumulation.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

      \n\t\t\t\t\t

      Read more >><\/h4>\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t
        \n
      • A two-way street:<\/strong> Insulin resistance drives liver fat accumulation, and excess liver fat worsens insulin resistance. Breaking this cycle starts with measurement.<\/li>\n
      • Diabetes and the liver:<\/strong> An estimated 70% of people with type 2 diabetes have concurrent fatty liver disease. Most haven\u2019t been screened \u2014 routine liver fat assessment in diabetes care remains a major unmet need.<\/li>\n
      • Metabolic syndrome clustering:<\/strong> Obesity, hypertension, dyslipidemia, and elevated glucose often co-occur with fatty liver. Addressing liver health means addressing metabolic health as a whole.<\/li>\n<\/ul>\n
        Sources: Younossi ZM et al., Hepatology 2016 (global epidemiology); EASL-EASD-EASO Clinical Practice Guidelines (J Hepatol, 2024).<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
        \n\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t\t\t
        \n\t\t\t
        \n\t\t\t<\/path><\/path><\/path><\/g><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t\t

        How to Measure Liver Fat<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t\t\t\t\t\t

        Compare testing methods: biopsy, MRI-PDFF, ultrasound, and modern point-of-care assessment.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

        \n\t\t\t\t\t

        Read more >><\/h4>\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t\t\t\t\t\t
          \n
        • No single \u201cbest\u201d test:<\/strong> Different methods answer different questions. Understanding the trade-offs helps patients and clinicians choose appropriately.<\/li>\n
        • Accessibility gap:<\/strong> MRI-PDFF is the non-invasive reference standard, but cost, scheduling, and infrastructure limit its reach. This is where point-of-care tools create the most value.<\/li>\n
        • The quantitative shift:<\/strong> From \u201clooks fatty on ultrasound\u201d to \u201cliver fat is 18%\u201d \u2014 quantitative assessment enables tracking, comparison, and evidence-based conversations.<\/li>\n<\/ul>\n
          See the Testing Methods comparison table below for a detailed breakdown.<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
          \n\t\t\t\t
          \n\t\t\t\t\t\t\t
          \n\t\t\t
          \n\t\t\t<\/circle><\/path><\/path><\/g><\/g><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
          \n\t\t\t\t\t

          Liver Health Self-Assessment<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
          \n\t\t\t\t\t\t\t\t\t

          Use a practical risk checklist to prepare better questions for your healthcare professional.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

          \n\t\t\t\t\t

          Read more >><\/h4>\t\t\t\t<\/div>\n\t\t\t\t
          \n\t\t\t\t\t\t\t\t\t
            \n
          • Risk doesn\u2019t mean disease:<\/strong> The checklist identifies factors associated with higher likelihood of fatty liver \u2014 it is a conversation starter, not a diagnosis.<\/li>\n
          • Prepare for your visit:<\/strong> Knowing your risk factors helps you have a more productive conversation with your clinician about whether liver fat assessment is appropriate.<\/li>\n
          • Scroll down<\/strong> to use the interactive checklist and see your personalized recommendation.<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
            \n\t\t\t\t\t